These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36137495)

  • 1. Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
    Bilani N; Crowley F; Mohanna M; Itani M; Yaghi M; Saravia D; Jabbal I; Dominguez B; Liang H; Nahleh Z
    Breast; 2022 Dec; 66():49-53. PubMed ID: 36137495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer.
    Pomponio M; Keele L; Hilt E; Burkbauer L; Goldbach M; Nazarian S; Fox K; Tchou J
    Ann Surg Oncol; 2020 May; 27(5):1671-1678. PubMed ID: 31686348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.
    Bilani N; Patel R; Crowley F; Tiersten A
    Oncologist; 2023 Dec; 28(12):1049-1054. PubMed ID: 37682780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
    Turashvili G; Wen HY
    Breast J; 2020 Jun; 26(6):1199-1207. PubMed ID: 32458521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer.
    Yaghi M; Bilani N; Dominguez B; Zerdan MB; Li H; Saravia D; Stone E; Nahleh Z
    Cancer Treat Res Commun; 2023; 34():100666. PubMed ID: 36525755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
    Weiser R; Haque W; Polychronopoulou E; Hatch SS; Kuo YF; Gradishar WJ; Klimberg VS
    Breast Cancer Res Treat; 2021 Feb; 185(3):667-676. PubMed ID: 33070279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
    Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
    Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
    Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
    Fujii T; Masuda H; Cheng YC; Yang F; Sahin AA; Naoi Y; Matsunaga Y; Raghavendra A; Sinha AK; Fernandez JRE; James A; Yamagishi K; Matsushima T; Schuetz R; Tripathy D; Tada S; Jackson RS; Noguchi S; Nakamura S; Acoba JD; Ueno NT
    Breast Cancer Res Treat; 2021 Sep; 189(2):455-461. PubMed ID: 34131830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
    Jahn B; Rochau U; Kurzthaler C; Hubalek M; Miksad R; Sroczynski G; Paulden M; Bundo M; Stenehjem D; Brixner D; Krahn M; Siebert U
    BMC Cancer; 2017 Oct; 17(1):685. PubMed ID: 29037213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer.
    Nash AL; Ren Y; Plichta JK; Rosenberger LH; van den Bruele AMB; DiNome ML; Westbrook K; Hwang ES
    Ann Surg Oncol; 2023 Apr; 30(4):2130-2139. PubMed ID: 36611067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
    Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
    Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
    Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
    Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.